Surgical Science Sweden Full Year 2024 Earnings: Misses Expectations

Surgical Science Sweden (STO:SUS) Full Year 2024 Results

Key Financial Results

• Revenue: kr884.1m (flat on FY 2023).
• Net income: kr131.6m (down 44% from FY 2023).
• Profit margin: 15% (down from 27% in FY 2023).
• EPS: kr2.58 (down from kr4.59 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Surgical Science Sweden Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 10%.

Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in Sweden.

Performance of the Swedish Medical Equipment industry.

The company's shares are down 12% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Surgical Science Sweden that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.